Φορτώνει......
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....
Αποθηκεύτηκε σε:
Τόπος έκδοσης: | Oncotarget |
---|---|
Κύριοι συγγραφείς: | , , , , , |
Μορφή: | Artigo |
Γλώσσα: | Inglês |
Έκδοση: |
Impact Journals LLC
2015
|
Θέματα: | |
Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4599296/ https://ncbi.nlm.nih.gov/pubmed/25938546 |
Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|